Urinary Neutrophil Gelatinase-associated Lipocalin as a Marker for Identification of Acute Kidney Injury and Recovery in Dogs with Gentamicin-induced Nephrotoxicity. by Palm, CA et al.
UC Davis
UC Davis Previously Published Works
Title
Urinary Neutrophil Gelatinase-associated Lipocalin as a Marker for Identification of Acute 
Kidney Injury and Recovery in Dogs with Gentamicin-induced Nephrotoxicity.
Permalink
https://escholarship.org/uc/item/56j2x476
Journal
Journal of veterinary internal medicine, 30(1)
ISSN
0891-6640
Authors
Palm, CA
Segev, G
Cowgill, LD
et al.
Publication Date
2016-01-04
DOI
10.1111/jvim.13819
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Urinary Neutrophil Gelatinase-associated Lipocalin as a Marker for
Identification of Acute Kidney Injury and Recovery in Dogs with
Gentamicin-induced Nephrotoxicity
C.A. Palm, G. Segev, L.D. Cowgill, B.E. LeRoy, K.L. Kowalkowski, K. Kanakubo, and J.L. Westropp
Background: Acute kidney injury (AKI) is associated with high mortality rates in dogs, which may be a consequence of
late recognition using traditional diagnostic tests. Neutrophil gelatinase-associated lipocalin (NGAL) is a protein-induced
during kidney injury that may identify AKI earlier than traditional tests.
Objectives/Hypothesis: To evaluate urinary NGAL (uNGAL) and uNGAL-to-urinary creatinine ratio (UNCR) as early
markers of kidney injury and recovery in an AKI model in dogs. It was hypothesized that these markers would document
AKI earlier than serum creatinine concentration.
Animals: Five purpose-bred dogs.
Methods: Prospective study. Acute kidney injury, defined as a > 50% increase in serum creatinine concentration above
baseline, was induced in dogs by gentamicin administration (8–10 mg/kg SC q8h). Blood and urine collected for biochemical
analyses and uNGAL and urinary creatinine concentrations, respectively, during AKI induction and recovery.
Results: Acute kidney injury was diagnosed significantly earlier based on a 7-fold increase in UNCR compared to
a > 50% increase in serum creatinine concentration (day 8; range, 2–10 mg/dl vs day 16; range, 14–19 mg/dl; P = .009). Dur-
ing recovery, the initial decrease in UNCR preceded the decrease in serum creatinine concentration by a median of 2 days.
The uNGAL changes paralleled UNCR changes, but the increase in uNGAL was triphasic; the initial peak occurred earlier
than UNCR (median, day 11 versus median, day 19).
Conclusions and Clinical Importance: The UNCR was early marker of gentamicin-induced AKI and its decrease docu-
mented onset of renal recovery. Additional studies are needed to validate this marker in dogs with naturally occurring renal
injury.
Key words: Acute kidney injury; Biomarker; Neutrophil gelatinase-associated lipocalin; uNGAL to urinary creatinine
ratio.
Acute kidney injury is characterized by an abruptand sustained decrease in glomerular filtration rate.
It is common in dogs, and is associated with high treat-
ment costs and high morbidity and mortality.1–3 The
overall mortality rate for human beings and dogs with
AKI is approximately 50%, but outcome is highly
dependent on etiology and available treatment
options.1–4 This high mortality rate has remained
almost unchanged, despite advances in diagnostic test-
ing and available treatments, including renal replace-
ment treatment.1–7 One of the speculated reasons for
this high mortality is late recognition of disease and
consequently a narrow window of opportunity for inter-
vention. Early grades of AKI may go undetected when
kidney function is assessed using traditional diagnostic
tests, such as serum creatinine concentration.
Neutrophil gelatinase-associated lipocalin (NGAL)
has been identified as 1 of the earliest and most
robustly induced proteins in both ischemic kidney injury
and in animal models of nephrotoxicity.8,9 It belongs to
the lipocalin superfamily and was identified as a compo-
nent of neutrophil granules. It is expressed during
inflammatory responses, but also is expressed in the
epithelial cells of various tissues.10 Normally, urinary
NGAL (uNGAL) is expressed at low concentrations,
but its expression is induced by renal tubular epithelial
injury. Plasma NGAL was found to be an accurate
marker of AKI in human patients undergoing cardiac
surgery.11 Urinary NGAL was reported as a marker for
AKI in dogs undergoing surgical procedures as a model
for AKI.12 In another study, we reported that a > 7-
fold increase in uNGAL-to-urinary creatinine ratio
(UNCR) above baseline discriminated AKI from other
types of urinary disease. Our previous study demon-
strated UNCR to be a specific marker, showing an
increase in dogs with naturally acquired AKI, but many
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of these dogs were affected by other comorbidities that
could have affected assessment of NGAL concentra-
tions. Furthermore, assessment of NGAL as a marker
for renal recovery was not performed in that study.13 In
an experimental model evaluating 2 dogs with gentam-
icin-induced AKI, uNGAL increased before serum crea-
tinine concentration, but dogs were euthanized before
recovery and NGAL was not followed during this phase
of disease.14 These collective observations suggest
NGAL has utility as an early biomarker of AKI in
dogs, but further evaluation in an experimental model
is needed to support these preliminary data and to
determine if increases in uNGAL are specific for kidney
damage and not other inflammatory comorbidities. In
addition, changes in uNGAL have not been reported
during the recovery phase of AKI, which may herald
the onset of kidney repair.
The aims of this study were to evaluate uNGAL con-
centration and UNCR as potential early markers of
both kidney injury and kidney recovery in normal dogs
with gentamicin-induced AKI. We hypothesized that
uNGAL concentration and UNCR would increase ear-
lier than serum creatinine concentration after gentamicin
administration and decrease earlier during the recovery
phase.
Materials and Methods
This protocol was approved by the Institutional Animal Care
and Use Committee at the University of California, Davis. All
dogs were adopted at the conclusion of the study.
Dogs
In this prospective study, 6 adult purpose-bred research dogs
were evaluated for inclusion in the study. Dogs were deemed
healthy based on normal physical examination findings and
absence of abnormalities on a CBC, serum biochemical analysis,
urinalysis, and urine culture.
Induction and definition of Acute Kidney Injury
Nephrotoxicity was induced by administration of gentamicina
(8 mg/kg SC) q8 h to each dog. If AKI (defined as a 50% increase
in serum creatinine concentration from baseline [day 0]) was not
established after 7 days, the dosage of gentamicin was increased to
10 mg/kg SC q8 h.15,16 Administration of gentamicin was discon-
tinued in individual dogs at the first documented increase in serum
creatinine concentration ≥50% above baseline. During AKI induc-
tion, serum creatinine concentration was evaluated twice daily to
ensure timely discontinuation of gentamicin as soon as AKI was
established, thereby attempting to mitigate development of severe
injury that would result in adverse clinical signs, irreversible kid-
ney injury, or both. Recovery of AKI was documented as a persis-
tent decrease in serum creatinine concentration from its peak after
discontinuation of gentamicin. Lactated ringer solutionb (1 L SC
q12 – q24 h) was administered only during the recovery period at
the investigator’s discretion to any dog that appeared hypodipsic.
Sample Collection
At baseline (day 0), CBC, serum biochemistry analysis, urinaly-
sis and urine culture were performed at the diagnostic laboratories
of the William R. Pritchard Veterinary Medical Teaching Hospital
using standard methodologies. Blood was collected for serum crea-
tinine, BUN, potassium, sodium, chloride, phosphorus, calcium
concentrations, and for packed cell volume and total solids deter-
minations, at baseline and after administration of gentamicin at
the following time points: twice daily during AKI induction, once
daily from the establishment of AKI until day 24, and then on
days 26, 28, 31, 35, 39, 46, and 60. Six milliliters of blood were
obtained from the jugular or lateral saphenous veins using a 22-
gauge needle. Urine was collected by antepubic cystocentesis
whenever possible or occasionally by voiding (at the same time
points as described for blood collections), because previous studies
documented that uNGAL and UNCR did not differ based on
method of urine collection.13 Urine-specific gravity (USG) was
measured using a standard refractometer. All blood and urine
samples were placed on ice immediately after collection and cen-
trifuged in a refrigerated centrifuge within 30 minutes of collec-
tion. Samples for biomarker measurement were stored at 80°C
pending batched analysis.
NGAL Analysis
The NGAL concentrations were measured in canine urine using
an ELISA kitc as previously described.13 Briefly, the kit contained a
plate with test wells that are precoated with a mouse monoclonal
antibody against canine NGAL, an additional site-specific biotiny-
lated canine NGAL monoclonal antibody, a reference standard,
and proprietary reagents. A standard curve for NGAL was created
using 8 dilutions (ranging from 0 to 400 pg/mL) of canine NGAL
reference standard, which were evaluated on the same plate as the
experimental samples. Both experimental samples and reference
standards were diluted 1:100 using a proprietary diluent and then
added to the anti-canine NGAL antibody-coated sample wells and
incubated for 1 hour at room temperature with gentle agitation.
After incubation, all wells were washed to remove unbound anti-
body, and the secondary biotinylated antibody was added and incu-
bated with agitation at room temperature for 1 hour. After the
second incubation, all wells were washed with a proprietary wash
solution and incubated with a streptavidin-horse radish peroxidase
reagent at room temperature with agitation for 1 hour. After this
incubation, a tetramethylbenzidine-based peroxidase substrate was
added for 10 minutes at room temperature in the dark for color
development. At 10 minutes, a dilute sulfuric acid stop solution
was added, and the optical density of the solution in the well was
measured at 450 nm using a plate reader. The concentrations of the
experimental samples were calculated from a standard curve of the
optical densities using curve-fitting software.d
Statistical analysis
Continuous variables (eg, time between identification of AKI
based on UNCR and serum creatinine concentration) were com-
pared using the Mann–Whitney U-test. Analyses were performed
using statistical software.e For all tests applied, P < .05 was con-
sidered statistically significant.
Results
One dog was excluded from the study because of the
presence of an E. coli bacterial cystitis. The included
dogs were 2-year old, female intact purpose-bred hound
dogs. Median body weight was 22.3 kg (range, 20–
22.7 kg).
The median serum creatinine concentration at base-
line (day 0) before gentamicin administration was
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1.0 mg/dL (range, 0.7–1.0 mg/dL). Median baseline
uNGAL and UNCR were 507 pg/mL (range, 142–
1,047 pg/mL) and 280 pg/mg (range, 185–608 pg/mg),
respectively. All other biochemical variables were within
the reference ranges before gentamicin administration.
Serum creatinine concentration remained unchanged
during the first 2 weeks of gentamicin administration.
All dogs required an increase in gentamicin dosage on
day 8 to induce a > 50% increase in serum creatinine
concentration. A > 50% increase in serum creatinine
concentration from baseline was documented in all dogs
on median day 16 (range, 14–19 days).
Urinary NGAL increased gradually until day 7 of
gentamicin administration, from a median baseline of
507 pg/mL (range, 142–1,047 pg/mL) to a median
uNGAL concentration of 1875 pg/mL (range, 285–
11,785 pg/mL). After day 7, median uNGAL increased
steeply, until it peaked at 166,000 pg/mL (range,
52,170–521,119 pg/mL) on day 19, which represented a
185-fold increase in median uNGAL concentration
compared to baseline. The initial change in UNCR par-
alleled the change in uNGAL and reached a > 7-fold
increase on median day 8 (range, 2–10 days) of gentam-
icin administration compared to median day 16 (range,
14–19 days; P = .009) to document a > 50% increase in
serum creatinine concentration. In contrast to UNCR,
the increase in uNGAL was triphasic, and the initial
uNGAL peak occurred at an earlier time point (median
day 11 versus median day 19 for UNCR). The maximal
increase in UNCR was more pronounced compared to
the increase in uNGAL (557- versus. 185-fold increase
from baseline, respectively). All dogs experienced
decreases in USG (ie, <1.012), and the decline in USG
paralleled the increases in UNCR; the peak UNCR cor-
responded temporally to the nadir of USG.
The UNCR decreased progressively after its peak
value on median day 19. During the recovery phase, the
decrease in median UNCR preceded the decrease in
serum creatinine concentration by 2 days (Fig 1F). In
contrast, uNGAL decreased initially on median day 10
but fluctuated before a sustained and progressive
decrease on median day 26; this sustained decrease in
uNGAL was apparent only at 5 days after the decrease
in serum creatinine concentration.
Discussion
The results of the present study indicate that uNGAL
and UNCR are consistent and early markers of gentam-
icin-induced AKI in dogs. Previously, a >7-fold increase
in UNCR above baseline concentration was shown to
discriminate AKI from other types of urinary disease
(eg, lower urinary tract disease, chronic kidney dis-
ease).13 The present study indicates that a diagnosis of
AKI using UNCR (based on a 7-fold increase from
baseline) can be made earlier than a diagnosis of AKI
using serum creatinine concentration (based on a 50%
increase from baseline) by a median of 8 days.
Although similar threshold values have not been estab-
lished for uNGAL, the uNGAL paralleled the changes
in UNCR, and these observations suggest both uNGAL
and UNCR are earlier markers of AKI compared to
serum creatinine concentration. Increases in UNCR
paralleled decreases in USG in all dogs, but AKI may
be missed if only monitoring for trends in USG, espe-
cially if animals are receiving fluid treatment or have
other comorbidities that result in low USG at the time
of evaluation.
One of the speculated reasons for the high and
almost unchanged mortality rate with AKI is late recog-
nition using current diagnostic markers, primarily serum
creatinine concentration. With traditional testing, AKI
is recognized most commonly when overt clinical mani-
festations occur or biochemical abnormalities suggestive
of severe kidney dysfunction are identified. Once a sub-
stantial reduction in kidney function is present, manage-
ment of AKI involves intensive supportive care, with
the requirement for hospitalization and possibly renal
replacement treatment. Despite intervention, severe
AKI is still associated with high mortality.3,4,17 To date,
there are no sensitive and specific markers routinely
used to identify AKI earlier than identified by serum
creatinine concentration.
The utility of early predictive biomarkers has been
demonstrated in human patients, where AKI is acquired
most commonly during hospitalization for treatment of
other conditions. In veterinary medicine, many dogs are
presented for treatment of adverse clinical signs and are
subsequently diagnosed with AKI at an advanced stage
of disease. At this stage, routine markers of AKI (eg,
serum creatinine and blood urea nitrogen concentra-
tions) are sensitive enough to diagnose the disorder.2
Nevertheless, a subset of dogs develop hospital-acquired
AKI or are evaluated at earlier and less advanced stages
of kidney injury (before overt failure is present), and
for this patient population, more sensitive markers are
required to diagnose the disease in a timely fashion. In
addition, more sensitive markers are needed to monitor
dogs that receive nephrotoxic drugs, to allow for identi-
fication of unknown factors that may lead to the initia-
tion of kidney injury and to allow for critical evaluation
of early interventions that may prevent development of
overt renal failure. Recently, the incidence of hospital-
acquired AKI in dogs, diagnosed based on >150% or
>0.3 mg/dL increase in serum creatinine concentration
from baseline, was shown to be as high as 12%.18 The
incidence of AKI may have been even higher if more
rigorous diagnostic criteria had been used for all cases,
as recommended by the International Renal Interest
Society (IRIS) AKI grading system (>0.3 mg/dL
increase in serum creatinine concentration from base-
line). Also, the diagnosis of hospital-acquired AKI may
have been documented more often if more sensitive
biomarkers, such as uNGAL, had been utilized. Some
dogs with undiagnosed mild forms of AKI might pro-
gress to overt kidney failure as a consequence of
delayed treatment, and early diagnosis may be critical
for improved outcomes.
In our study, changes from baseline for serum crea-
tinine concentration and UNCR were used to document
AKI. We selected a more rigorous increase in serum
creatinine concentration to define AKI (eg, >50%
202 Palm et al
increase from baseline) than proposed by recent IRIS
AKI guidelines to ensure establishment of intrinsic renal
injury and to avoid misclassification of AKI that could
occur with creatinine assay variation or mild, unde-
tectable dehydration and prerenal azotemia.13 Nonethe-
less, even using the IRIS criteria, the diagnosis of AKI
was made significantly earlier when changes in uNGAL
or UNCR were used to document kidney injury, as
compared to serum creatinine concentration, a finding
that is in agreement with studies in human patients.19
We have reported previously that UNCR was
increased in dogs with established AKI, chronic kidney
disease and urinary tract infection.13 In this previous
study, a 7-fold increase in UNCR from baseline dis-
criminated AKI from other urinary diseases.13 The pre-
vious study also demonstrated that the increase in
UNCR precedes the increase in serum creatinine con-
centration, but that study was not designed to assess
how early the diagnosis of AKI can be made using
UNCR compared to serum creatinine concentration.
The present study further demonstrates that uNGAL
and UNCR are early and consistent markers of AKI
compared to serum creatinine concentration because all
dogs experienced a > than 7-fold increase in UNCR
after gentamicin administration, but also that the
increase in UNCR preceded the prediction of AKI
Figure 1. (A–E) Urinary NGAL/creatinine ratio (UNCR) and serum creatinine concentration after gentamicin administration in all 5
dogs. The day of development of acute kidney injury, based on a 7-fold increase in UNCR and 50% increase in serum creatinine concen-
tration is depicted by arrows. (F) Sequential changes in mean and standard deviation of urinary NGAL/creatinine ratio (UNCR) and
serum creatinine concentration after gentamicin administration during induction of acute kidney injury, and during recovery from acute
kidney injury. Occasionally, there is an overlap in the standard deviation bars for the UNCR and creatinine lines. Note that each individ-
ual standard deviation line arises from the individual dataset that it represents and ends on the small horizontal standard deviation line.
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based on serum creatinine concentration by a median of
8 days.
In previous studies evaluating NGAL in dogs with
naturally occurring kidney disease, comorbidities (eg,
sepsis, heatstroke) existed and might have affected
serum NGAL and uNGAL concentrations.13 This pre-
sent study evaluated uNGAL and UNCR in an
experimental population of dogs that did not have
confounding comorbidities that could contribute to
the documented increase in serum NGAL and
uNGAL concentrations, supporting the conclusion
that changes in NGAL were specific to kidney injury
and not caused by other underlying inflammatory
conditions.
We also evaluated the recovery phase of AKI, which
has not been done in previous studies. We found that
the recovery phase of AKI could be identified earlier
based on UNCR compared to serum creatinine concen-
tration. The UNCR started to decrease 2 days earlier
than the decrease in serum creatinine concentration.
This finding suggests the decrease in UNCR may be
an earlier marker of renal repair compared to a
decrease in serum creatinine concentration. A larger
population of dogs would be required to determine if
this decrease will be statistically significant. Although
the 2-day difference might not seem pronounced, early
detection of recovery is important to project hospital-
ization costs, and timely identification of renal recovery
might influence therapeutic management, assessment of
outcome, and decisions about euthanasia. Monitoring
of uNGAL as a marker of active and potentially ongo-
ing tubular injury also has the potential to provide
information regarding active repair of the kidney.
Creatinine as a filtration marker is unable to document
this process of repair. In the current study, from
approximately day 25 to day 60, UNCR progressed
from markedly increased values to baseline, at a time
when serum creatinine concentration was relatively sta-
tic. This response suggests that tubular injury still was
active but improving throughout this interval. The
decrease in serum creatinine concentration reflects
improvement in kidney function, and therefore is
delayed as compared to NGAL. Measurement of
NGAL provides insights into the status of the disease
process, which has not been previously identified with
traditional markers.
The cause of the triphasic response of uNGAL dur-
ing the maintenance phase of kidney injury (between
induction and recovery) is not readily apparent, nor is
the difference in response between uNGAL and UNCR
during this phase. The fluctuations in uNGAL may rep-
resent waves of parenchymal injury and NGAL induc-
tion and excretion throughout this phase that are not
reflected when uNGAL is indexed to urinary creatinine
concentration. The issue of indexing urinary biomarkers
markers (eg, to creatinine) remains a controversial and
unresolved subject, and it is conceivable the unindexed
uNGAL provides predictions about the extent and tim-
ing of the kidney insult that are masked by creatinine
indexing. Urinary creatinine (a filtration marker) and
uNGAL (an active tubular injury marker) likely docu-
ment independent processes occurring in different seg-
ments of the nephron, and indexing 1 process by the
result of the other may mask their independent behav-
iors. We suggest that oscillations in uNGAL reflect
waves of insult or active injury to the tubular epithe-
lium ongoing in the kidney over time that likely are
independent of the secondary or subsequent changes in
the filtration of creatinine which could modify these
observations. The indexing of urinary biomarkers
should be further evaluated.
Our study has some limitations. The first limitation
is the small number of dogs evaluated. We attempted
to overcome this problem by extensive serial evaluation
of the study animals to provide greater time resolution
for the identified changes. Second, the study design
evaluated the utility of UNCR and uNGAL in a single
animal model of AKI and therefore might not repre-
sent the changes in kidney damage associated with
other etiologies. Other studies have, however, indicated
that NGAL is increased in several etiologies of AKI,
and we believe these results will likely apply to dogs
with a broad array of naturally acquired AKI, but fur-
ther investigation is warranted.13 In some cases, such
as nephrotoxic drugs, baseline uNGAL measurements
could be obtained before administration, allowing for
evaluation of changes in uNGAL from baseline, as was
done in our study. To more widely apply the use of
AKI biomarkers in clinical practice, the upper limits of
uNGAL and UNCR must be evaluated in large num-
bers of clinical patients so that cut-off values can be
obtained for use when baseline values are not avail-
able.
In conclusion, this study documented that uNGAL
and UNCR may be useful diagnostic tools for the early
detection of gentamicin-induced AKI, and they also
may serve as early markers for recovery from AKI.
Additional studies are needed to validate the diagnostic
utility of these markers in clinical settings associated
with diverse causes of AKI and to define the most
appropriate index to express changes in NGAL excre-
tion.
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